Belite Bio Q2 net loss widens on higher expenses

Belite Bio

13/08/2026 02:55

Overview
US retinal disease drug developer's Q2 net loss widened as R&D and SG&A expenses increased
FDA accepted NDA for tinlarebant with Priority Review for Stargardt disease
Company reported positive secondary endpoint data from Phase 3 DRAGON trial of tinlarebant

Result Drivers
R&D EXPENSES - Higher R&D expenses were mainly due to a royalty payment for a milestone achieved under the license agreement, increased manufacturing costs, and consultant fees
SG&A EXPENSES - SG&A expenses increased due to team expansion and higher professional service fees
INTEREST INCOME - Other income rose due to higher interest earned on bank deposits and U.S. treasury securities

Company press release: ID:nGNX1f22Lj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$28.41 mln
 
Q2 Income From Operations
 
-$34.91 mln
 
Q2 Operating Expenses
 
$34.91 mln
 
Q2 Pretax Loss
 
$28.36 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Belite Bio, Inc is $207.50, about 16% above its August 12 closing price of $178.94

Reuters Recommended Reads
Aug 12 - Eloxx Pharmaceuticals Q2 net loss widens on higher expenses
Aug 11 - Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses
Aug 11 - Inhibikase Q2 net loss widens on higher R&D, SG&A costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)